United Kingdom

Biospecifics Technologies Corp (BSTC.OQ)

BSTC.OQ on NASDAQ Stock Exchange Global Market

23 Feb 2018
Change (% chg)

$1.39 (+3.60%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Biospecifics Technologies reports Q3 eps of $0.37
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Biospecifics Technologies Corp ::Biospecifics Technologies Corp reports Q3 2017 financial results.Q3 revenue $6.5 million versus $6.9 million.Q3 earnings per share $0.37.As of september 30, 2017, co had cash & cash equivalents & investments of $61.3 million.  Full Article

Biospecifics Q2 earnings per share $0.35
Tuesday, 9 Aug 2016 

Biospecifics Technologies Corp : Q2 earnings per share $0.35 . Biospecifics technologies corp. Reports second quarter 2016 financial results .Q2 revenue rose 32 percent to $6.2 million.  Full Article

Biospecifics Technologies positive results from phase 2 trial of CCH
Monday, 13 Jun 2016 

Biospecifics Technologies Corp : Biospecifics technologies corp. Announces positive top-line results from phase 2 trial of cch for treatment of human lipoma . Trial met its primary endpoint of reduction in visible surface area of target lipomas relative to placebo . There were no serious adverse events reported during trial .Announces Positive Top-Line results from phase 2 trial of cch for treatment of human lipoma.  Full Article

BioSpecifics Technologies Q1 earnings per share $0.39
Tuesday, 10 May 2016 

Biospecifics Technologies Corp : Total revenue for Q1 ended march 31, 2016 was $6.6 million , compared to $5.6 million for same period in 2015 . BioSpecifics Technologies Corp says co expects to initiate a clinical trial of CCH in uterine fibroids in second half of 2016 . Line results for its trial of cch in human lipoma in june of 2016 . BioSpecifics Technologies Corp. Reports first quarter 2016 financial results .Q1 earnings per share $0.39.  Full Article